

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3387147

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
SHIH-CHONG TSAI	12/01/2014
TA-TUNG YUAN	12/10/2014
SHIH-CHI TSENG	12/01/2014
JIANN-SHIUN LAI	12/12/2014
CHIA-CHENG WU	11/28/2014
CHAO-YANG HUANG	12/01/2014
YA-WEI TSAI	12/02/2014
YING-YUNG LOK	12/02/2014
CHUNG-HSIUN WU	12/02/2014

**RECEIVING PARTY DATA**

<b>Name:</b>	DEVELOPMENT CENTER FOR BIOTECHNOLOGY
<b>Street Address:</b>	NO. 101, LANE 169, KANGNING ST.
<b>City:</b>	NEW TAIPEI CITY
<b>State/Country:</b>	TAIWAN
<b>Postal Code:</b>	221
<b>Name:</b>	DCB-USA LLC
<b>Street Address:</b>	1007 N. ORANGE STREET, 9TH FLOOR
<b>City:</b>	WILMINGTON, NEW CASTLE
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19801

**PROPERTY NUMBERS Total: 2**

Property Type	Number
<b>Application Number:</b>	14588212
<b>PCT Number:</b>	US2014073013

**CORRESPONDENCE DATA**

Fax Number: (713)228-8778

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: (713)228-8600

PATENT

**Email:** dwieser@oshaliang.com  
**Correspondent Name:** T. CHYAU LIANG, PH.D.  
**Address Line 1:** OSHA LIANG LLP  
**Address Line 2:** 909 FANNIN STREET, SUITE 3500  
**Address Line 4:** HOUSTON, TEXAS 77010

**ATTORNEY DOCKET NUMBER:** 17787021001-ASSN (DCB)

**NAME OF SUBMITTER:** T. CHYAU LIANG, PH.D.

**SIGNATURE:** /T. Chyau Liang/

**DATE SIGNED:** 06/08/2015

**Total Attachments: 2**

source=17787021001\_ASSN-DCB#page1.tif

source=17787021001\_ASSN-DCB#page2.tif

## ASSIGNMENT – WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned individual(s) (referred to herein as the "INVENTOR(S)") hereby assign, transfer, and set over to:

### DEVELOPMENT CENTER FOR BIOTECHNOLOGY

having the following address: No. 101, Lane 169, Kangning St.  
New Taipei City 221  
TAIWAN ROC

AND

### DCB-USA LLC

having the following address: 1007 N. Orange Street, 9<sup>th</sup> Floor  
Wilmington, New Castle, Delaware 19801

(referred to herein as "COMPANY"), its successors, and assigns, the entire right, title, and interest, worldwide, in and to the invention known by the following title:

### HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY

for which the INVENTOR(S) or COMPANY has/have made an application for patent in the United States of America, together with said patent application, all divisions, continuations, continuations-in-part, reissues, and extensions thereof, and all Letters Patent (domestic and foreign) which may be granted therefor. Such interest represents the entire ownership of said applications and Letters Patent when granted and is to be owned by COMPANY, its successors, and assigns, or their legal representatives, for the full and entire term for which such Letters Patent may be granted or extended, as fully and entirely as the same would have been enjoyed by the INVENTOR(S) if this assignment had not been made.

In addition, the undersigned INVENTOR(S) each hereby agrees:

1. To sign and execute any further documents which may be necessary or desirable, lawful, and proper in connection with the prosecution of all applications for patent(s) on the INVENTION in the United States, including without limitation said application and all divisions, continuations, continuations-in-part, amendments thereof, and all interference proceedings associated therewith, or otherwise necessary or desirable to secure the title thereto to COMPANY;
2. To execute all papers and documents and to perform all lawful acts which may be necessary in connection with claims to priority or otherwise under the International Convention for the Protection of Industrial Property or similar treaties or agreements;
3. To perform all lawful affirmative acts which may be necessary to obtain the grant of a valid and enforceable patent to COMPANY.

The undersigned INVENTOR(S) each hereby authorizes and requests the Commissioner of Patents and Trademarks in the United States to issue any and all Letters Patent resulting from said application, including without limitation any division, continuation, continuation-in-part, or reissue thereof to COMPANY.

The undersigned INVENTOR(S) each hereby grants to the firm of OSHA LLANG LLP the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for the recordation of this document.

**OSHA**

IN WITNESS WHEREOF, this Assignment has been executed by each of the undersigned individuals on the date appearing by such individual's signature:

<u>Dec. 01, 2014</u> Date	1 <sup>st</sup> Inventor Signature: <u><i>Shih-Chong Tsai</i></u> Print or Type Name: <u>Shih-Chong Tsai</u>
<u>Dec. 10, 2014</u> Date	2 <sup>nd</sup> Inventor Signature: <u><i>Ta-Tung Yuan</i></u> Print or Type Name: <u>Ta-Tung Yuan</u>
<u>Dec. 01, 2014</u> Date	3 <sup>rd</sup> Inventor Signature: <u><i>Shih-Chi Tseng</i></u> Print or Type Name: <u>Shih-Chi Tseng</u>
<u>Dec. 12, 2014</u> Date	4 <sup>th</sup> Inventor Signature: <u><i>Hsiun-Shun Lai</i></u> Print or Type Name: <u>Hsiun-Shun Lai</u>
<u>Nov. 28, 2014</u> Date	5 <sup>th</sup> Inventor Signature: <u><i>Chia-Cheng Wu</i></u> Print or Type Name: <u>Chia-Cheng Wu</u>
<u>Dec. 01, 2014</u> Date	6 <sup>th</sup> Inventor Signature: <u><i>Chao-Yang Huang</i></u> Print or Type Name: <u>Chao-Yang Huang</u>
<u>Dec. 02, 2014</u> Date	7 <sup>th</sup> Inventor Signature: <u><i>Ya-Wei Tsai</i></u> Print or Type Name: <u>Ya-Wei Tsai</u>
<u>Dec. 02, 2014</u> Date	8 <sup>th</sup> Inventor Signature: <u><i>Ying-Yung Lok</i></u> Print or Type Name: <u>Ying-Yung Lok</u>
<u>Dec. 02, 2014</u> Date	9 <sup>th</sup> Inventor Signature: <u><i>Chung-Hsiun Wu</i></u> Print or Type Name: <u>Chung-Hsiun Wu</u>

When this Assignment is not filed concurrently with the patent application, the following identifying information may be added after execution:

U.S. Application Serial No.: U.S. 14/588,212 filed 12/31/2014 and  
Filing Date: PCT/US2014/73013 filed 12/31/2014

OSHALIANG